A STUDY OF THE ANTIOXIDANT EFFECTS OF IRANIAN CAPTOPRIL ON PATIENTS WITH HYPERTENSION AND HEART FAILURE

Myocardial ischemia, cerebral ischemia and myocardial infarction arethe most important complications of hypertension and atherosclerotic disease in developing countries. Angiotensin converting enzyme (ACE) inhibitors are among the drugs used to treat hypertension and heart failure. Captopril is an ACE-inhibitor which also has antioxidant properties. This study was conducted to assess the antioxidant effects of Iranian Captopril on malondialdehyde (MDA), conjugated dienes (CD) and serum antioxidant capacity before and after treatment. This interventional prospective single-blind study was conducted on 34 mildlyhypertensive individuals and 34 patients with stage I and II heart failure. MDA, CD andserum antioxidant capacity were measured in all samples. The patients were then given50 mg Captopril tablets 2-3 times daily. The measurements were repeated 1.5 months later. Comparison of mean MDA, CD and serum antioxidant capacity in hypertensivepatients and patients with heart failure before and after drug administration revealed nosignificant difference in any of the parameters studied. Existing evidence is suggestive of the strong antioxidative properties ofCaptopril in vitro, although these effects have not been borne out by some studies. In the present study, comparison of MDA, CD and serum antioxidants before and after the period of treatment with Iranian Captopril did not reveal any statistically significant difference.